pharma news

View All

Pharma News
Good news for Kite’s KTE-X19, and Aquestive’s Libervant; and a commercialization deal between ReForm Biologics, MilliporeSigma

FDA has accepted Biological License Application submitted by Kite for its CAR-T cell therapy- KTE-X19, for relapsed or refractory mantle cell lymphoma (MCL) The drug- KTE-X19, which is an investigational chimeric antigen receptor (CAR) T cell therapy treatment method for curing relapsed or refractory mantle cell...

Find More

Pharma News
Immune cells for age-related diseases; Regeneron’s antibody for 2019-nCoV; FDA nods for hydrogel injection

Activated immune cells responsible for improving age-related diseases  The main culprits of the inflammatory responses associated with asthma are Interleukins IL-33 and IL-5. There has been researching going on, and the researchers at Albany Medical College discovered that if these two signalling molecules ...

Find More

Pharma News
First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint; Insmed’s shares Soares

The US FDA has given its recommendation to the Aimmune Therapeutics’ drug, Palforzia, the first-ever treatment for Peanut Allergy. Palforzia is an oral immunotherapy, set to address the unmet needs in the Peanut market, reducing the incidence and severity of allergic reactions, including anaphylaxis, which may ...

Find More

pharma news
Annovis announces IPO results; Conatus merges with Histogen; Novartis discontinues its generic journey

A Philadelphia-based pharmaceutical, Annovis Bio, has raised USD12 million by listing its 2 million shares at USD 6 each. The company has managed to net USD 2 million more by offering 40% more shares.  The company plans to use the funds raised to address the unmet needs in the Alzheimer’s disease market...

Find More

Pharma News
Acceleron Pharma’s drug sotatercept touches the phase 2 mark; GT Medical receives nod for GammaTile; New treatment strategy for Parkinson’s disease

The drug, sotatercept of Acceleron Pharma, touches the phase 2 mark Acceleron Pharma, a clinical-stage biopharmaceutical company based in Boston, Massachusetts with a primary aim on the development of medicines that regulate the transforming growth factor-beta (TGF-β) superfamily of proteins that play significan...

Find More

Pharma News
Tepezza receives approval; a new way to treat Alzheimer’s

Horizon Therapeutics has become the first company to receive the regulatory approval of its drug Tepezza for the cure of Thyroid Eye Tepezza (teprotumumab-trbw) is the first-ever treatment approved for thyroid eye is a progressive autoimmune disorder hampering the ability of vision. The drug was approved under P...

Find More

Pharma News
Thumbs down to NKTR-181, Lilly expands its insulin armamentarium

The US FDA has voted down Nektar Therapeutics’ opioid painkiller NKTR-181, designed to treat lower back pain.  The FDA’s Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee unanimously has decided not to recommend the use of the painkiller, ta...

Find More

pharma news
Eli Lilly to acquire Dermira, Boehringer buys Enleofen’s IL-11 platform, Biogen acquires Pfizer’s Alzheimer’s drug

Eli Lilly has announced to buy a biopharmaceutical company, Dermira, for a whopping sum of USD 1.1 Billion in an all-cash transaction. Through the acquisition, Eli Lilly is planning to expand its immunology pipeline by adding lebrikizumab, which is a novel, investigational, monoclonal antibody. The drug is desi...

Find More

Pharma News
Novome raises USD 33M, Buyout of Bioniz, Adagene raises USD 69M

A biotech company Novome Biotechnologies is developing novel live medicines for chronic diseases, has raised USD 33 Million in Series A financing. The financing was led by DCVC Bio with participation from seed investor 5AM Ventures, Alta Partners, Alexandria Venture Investments and Mayo Clinic. The company plan...

Find More

Pharma News
Nunaps raises USD 4.2M; Arcutis files for USD 100M IPO

A South Korean startup therapeutics company Nunaps has successfully raised USD 4.2 Million around 5 billion won in a Series A round.  The investment was made by the K Partners, KTB Network, and K2 Investment Partners. Nunaps is digital therapeutics and is planning to use the funds to build its digital thera...

Find More